Combined treatment of multiple sclerosis

Details Combined treatment of multiple sclerosis Combined treatment of multiple sclerosis

2005-03-22

2005-03-22

Kemmerer, Elizabeth (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C424S085600, C514S002600, C530S399000

Reexamination Certificate

active

06869600

ABSTRACT:
The use of growth hormone (GH) together with an interferon (IFN) to produce a pharmaceutical composition for treating multiple sclerosis and/or other demyelinating diseases is disclosed. Disclosed are also pharmaceutical compositions for treating multiple sclerosis and/or other demyelinating diseases. Disclosed are also pharmaceutical compositions for the simultaneous, separate or sequential use of its active ingredients for the above specified therapy. In particular, the advantage of EP0003504 of GH together with IFN-β to produce a pharmaceutical composition for the treatment of multiple sclerosis are shown.

REFERENCES:
patent: 4898856 (1990-02-01), Aroonsakul
patent: 5370870 (1994-12-01), Wong
patent: 5426096 (1995-06-01), Sonksen et al.
patent: 5780021 (1998-07-01), Sobel
patent: 5846526 (1998-12-01), Cummins
patent: 6187750 (2001-02-01), Chein
patent: 6297212 (2001-10-01), Fahy
patent: 6485480 (2002-11-01), Berwitt
patent: WO 9207578 (1992-05-01), None
Edwards et al. (Jun. 1992) “In Vivo Administration of Recombinant Growth Hormone or Gamma Interferon Activates Macrophages: Enhanced Resistance to Experimental . . . ” Infection and Immunity 60(6): 2514-2521.*
Cleland and Jones (Oct. 1996) “Stable Formulations of Recombinant Human Growth Hormone and Interferon-g for Microencapsulation in Biodegradable Microspheres.” Pharmaceutical Research 13(10): 1464-1475.*
Ye et al., In vivo actions of insulin-like growth factor-I (IGF-I) on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice,The Journal of Neuroscience,15(11):7344-7356 (1995).
Yao et al., Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis,Proc. Natl. Acad. Sci. USA.92:6190-6194 (1995).
Yao et al., Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis,Life Sciences,58:(16)1301-1306 (1996).
Yao et al., Cryogenic spinal cord injury induces astrocytic gene expression of insulin-like growth factor I and insulin-like growth factor binding protein 2 during myelin regeneration,Journal of Neuroscience Research,40:647-659 (1995).
Ussing, Zinc in the anterior pituitary of rat: a histochemical and analytical work,Neuroendocrinology,45:233-242 (1987).
Singh et al., Modified forms of human growth hormone with increased biological activities,Endo,94(3):883-891 (1981).
Shepard et al., A single amino acid change in IFN-β1abolishes its antiviral activity,Nature,294:563-566 (1981).
Martia et al., Human growth hormone: complementary DNA cloning and expression in bacteria,Science,205:602-607 (1979).
Mark et al., Site-specific mutagenesis of the human fibroblast interferon gene,Proc. Natl. Acad. Sci. USA,81:5662-5666 (1984).
Quigeley et al., Chronic relapsing experimental autoimmune encephalomyelitis: effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defects,Journal of Neuropathology and Experimental Neurology,57:426-438 (1998).
Lewis et al., Altered proteolytic cleavage of human growth hormone as a result of deamidation,The Journal of Biological Chemistry,11645-11650 (1981).
Lewis et al., A naturally occurring structural variant of human,The Journal of Biological Chemistry,253:2679-2687 (1978).
Lewis et al., Enhancement of the hyperglycemic activity of human growth hormone by enzymic modification,Endo,101(5)1587-1603 (1977).
Komoly et al., Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination,Proc. Natl. Acad. Sci. USA,89: 1894-1898 (1992).
Hsiung et al., Use of bacteriocin release protein inE. colifor excretion of human growth hormone into the culture medium, Bio/Technology, 7:267-271 (1989).
Graf et al., Human somatotropin,The Journal of Biological Chemistry,257:2365-2369 (1982).
Goeddel et al., Direct expression inEscherichia coliof a DNA sequence coding for human growth hormone,Nature,281:544-548 (1979).
Gertler et al., Inhibition of lactogenic activities of ovine prolactin and human growth hormone (hGH) by a novel form of a modified recombinant hGH,Endo,118:720-726 (1986).
Galli et al., Apoptosis in cerebellar granule cells is blocked by high KCL, forskolin, and IGF-1 through distinct mechanisms of action: The involvement of intracellular calcium and RNA synthesis,The Journal of Neuroscience,15(2):1172-1179 (1995).
Fernandez et al., Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia,Proc. Natl. Acad. Sci. USA,95:1253-1258 (1998).
Dore et al., Rediscovering an old friend, IGF-1: potential use in the treatment of neurodegenerative diseases,TINS,20(8):326-331 (1997).
Derynck et al., Isolation and structure of a human fibroblast interferon gene,Nature,285:542-547 (1980).
De Pablo et al., The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors,TINS,18:143-151 (1995).
DeNoto et al., Human growth hormone DNA sequence and mRNA structure: possible alterative splicing,Nucleic Acids Research,9:3719-3731 (1981).
Chen et al., The human growth hormone locus: nucleotide sequence, biology, and evolution,Genomics,4:479-497 (1989).
Bewley et al., Sequence comparison of human pituitary growth hormone, human chronic somatomammotropin, and ovine pituitary growth and lactogenic hormones,Int. J. Peptide Protein Res.,4:281-287 (1972).
Becker et al., Isolation and characterization of a sulfoxide and a desamido derivative of biosynthetic human growth hormone,Biotechnology and Applied Biochemistry,10:326-337 (1988).
ARTICLES—Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis,Lancet,352:1498-1504 (1998).

Affiliated with

Also associated with

Rating

Combined treatment of multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined treatment of multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined treatment of multiple sclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3402969